单剂基孔肯雅疫苗VLA1553接种后四年中和抗体持久性
本研究为3b期开放标签单臂长期随访,纳入关键3期试验中363名VLA1553接种者的子集,评估抗体持久性。第4年254人随访中血清反应率为94.5%(95%CI 90.9%~97.0%),GMT从第29天3542降至第4年589,仍远超血清反应阈值150。单剂接种后中和抗体至少持久4年。
要点
- 单剂VLA1553接种后第4年血清反应率94.5%,GMT 589远超阈值150
- ≥65岁成人抗体持久性与年轻成人相似
- VLA1553已在欧盟、巴西、加拿大和英国获批用于基孔肯雅热预防
核心结论
- 单剂VLA1553接种后中和抗体滴度至少持久4年,且远超血清反应阈值150。
研究设计与样本
- 3b期开放标签单臂长期随访研究,纳入关键3期试验中363名VLA1553接种者子集,该关键试验共4115名成人接种VLA1553或安慰剂。
- 第4年254人仍在随访,女性略多于男性,人群以白人为主且无西班牙裔或拉丁裔背景。
主要发现
- 第4年血清反应率为94.5%(240/254,95%CI 90.9%~97.0%)。
- 长期随访队列第29天GMT为3542,第1年1056,第2年785,第3年737,第4年589。
- ≥65岁成人抗体持久性与年轻成人全程随访相似。
关键数值与推荐
- 监管机构接受的免疫学替代终点为50%微斑减少中和试验滴度(μPRNT50)≥150。
- 第4年GMT 589 considerably超过血清反应阈值150。
临床怎么用
- 为前往或居住在基孔肯雅病毒流行区的个体提供单剂VLA1553接种,可预期至少4年的中和抗体持久性。
- ≥65岁成人接种后抗体持久性与年轻成人相似,无需因年龄调整接种策略。
局限性
- 本研究为开放标签单臂设计,无安慰剂对照。
- 随访人群以白人为主且无西班牙裔或拉丁裔背景,代表性有限。
- 第4年随访人数较基线减少(254/363)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
VLA1553 is a live-attenuated chikungunya virus vaccine approved for active immunization, in the EU, Brazil, Canada and the UK, as a prophylactic measure for individuals travelling to or living in areas where the chikungunya virus is circulating. Due to the unpredictable epidemic occurrence of chikungunya, a 50% micro-plaque reduction neutralization test titre (μPRNT50) of ≥150, was previously accepted by regulators as an immunological surrogate endpoint that is reasonably likely to predict clinical benefit. At this point in time, this phase 3b open-label, single-arm long-term focuses on antibody persistence in a subset (N = 363) of VLA1553 vaccinees from a pivotal phase 3 trial (Schneider et al., 2023) where 4115 adult participants received VLA1553 or placebo. At Year 4, 254 participants remained in follow-up with slightly more females than males. The population is predominantly White with no Hispanic or Latino background. The seroresponse rate was 94.5% (240/254, 95% CI 90.9% to 97.0%). The Day 29 GMT for the long-term follow-up cohort was 3542, and remained high with 1056 at Year 1, 785 at Year 2, 737 at Year 3 and 589 at Year 4, considerably exceeding the seroresponse threshold of 150. In adults aged ≥65 years, antibody persistence was similar to younger adults throughout the follow-up. Single dose vaccination with our live-attenuated chikungunya virus vaccine VLA1553 resulted in persistent neutralizing antibody titers well above the defined seroresponse threshold for at least 4 years.
引用
- Sattler N, Scheiblauer S, Hochreiter R, et al. Chikungunya virus-neutralizing antibody persistence four years after single-dose vaccination with VLA1553 (IXCHIQ®). Vaccine. 2026. PMID: 42250475. doi:10.1016/j.vaccine.2026.128787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。